

## 4DMedical signs SaaS contracts to expand access into Detroit and Memphis

22<sup>nd</sup> November 2023

### Highlights

- Following XV LVAS<sup>®</sup> reimbursement, 4DMedical wins SaaS contracts in the U.S.
- Outpatient practices in Detroit and Memphis sign agreements to perform commercial XV LVAS<sup>®</sup> scans commencing 1 January

**Melbourne, Australia, 22<sup>nd</sup> November 2023:** Respiratory imaging technology company 4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”) today announces that it has signed agreements to deliver XV LVAS<sup>®</sup> scans at imaging facilities located in the Detroit and Memphis communities.

### XV LVAS<sup>®</sup> coverage expands into Detroit and Memphis

Last week the Company announced the U.S. Centres for Medicare & Medicaid Services (CMS) had approved reimbursement for 4DMedical’s XV LVAS<sup>®</sup> at a rate of US\$299 per procedure effective 1 January 2024.

Following this milestone, PrecisionIR, a radiology practice in Detroit, Michigan, has signed a SaaS agreement with 4DMedical to offer XV LVAS<sup>®</sup> scans in their outpatient clinic beginning on 1 January 2024. In parallel, a second independent outpatient imaging facility, Memphis Vascular Center, in Memphis, Tennessee, has also signed to perform the same service.

Outpatient facilities provide patients with an alternative to hospital networks, thereby increasing patient and referrer access to XV LVAS<sup>®</sup> exams, and in an environment that is often seen as more convenient and patient-centric.

This immediate success illustrates the impact of reimbursement on uptake in the U.S. market. These agreements demonstrate a successful and scalable pathway to additional revenue, which 4DMedical is pursuing in parallel with its strategy of partnering with traditional hospital providers.

### Detroit clinician excited to offer XV LVAS<sup>®</sup> to his community

Dr. S. Andrew Vartanian, board certified Interventional Radiologist and Medical Director of PrecisionIR, said “At PrecisionIR, we diagnose and treat patients like family and continually look to improve the way we serve our community and referrers. 4DMedical’s XV Technology<sup>®</sup> enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies as they breathe,” notes Dr. Vartanian. “It can also help us exclude lung pathologies as the cause for symptoms, such as unexplained shortness of breath.”

“We recently learned of 4DMedical and the advanced technology they bring to lung health diagnostics. We also share their concern for military veterans exposed to toxic burn pits in Iraq and Afghanistan. 4DMedical’s XV LVAS<sup>®</sup> analytical software enables us to deliver more precision in lung health, an area often devoid of imaging innovation but impacting so many patients.”

Dr. Vartanian also says, “The new test takes approximately 5 minutes, is non-invasive, uses no potentially harmful contrast agents and as of 1<sup>st</sup> January, 2024, is eligible for reimbursement with a CMS CPT

For personal use only

#### Melbourne

Level 7 Melbourne Connect  
700 Swanston Street  
Carlton VIC 3053  
Tel: +61 (3) 9545 5940

#### Los Angeles

21255 Burbank Boulevard  
Suite 120  
Woodland Hills CA 91367  
Tel: +1 (818) 403-8490

4DMedical Limited  
ABN: 31 161 684 831  
Email: [info@4DMedical.com](mailto:info@4DMedical.com)  
[www.4DMedical.com](http://www.4DMedical.com)



code. Providing 4DMedical technology to our patients beginning in January is exciting, but equally is the opportunity to scan the veteran community in need of answers.”

**4DMedical MD/CEO and Founder Andreas Fouras said:**

*I am thrilled to see imaging facilities being brought online to serve patients in the communities of Detroit and Memphis. Not all patients needing scans want to visit a hospital environment for a lung assessment, and we are pleased to grow these options in the U.S., in parallel with expanding our traditional hospital providers.*

*That we are signing on partners before January 1 when CMS payment becomes available, and within just a few days of the announcement by CMS, highlights the game changing nature of access to reimbursement. I have never been more excited by the size and scope of our near-term commercial opportunities, and I look forward to sharing this progress over coming weeks and months.*

–ENDS–

Authorised by the 4DMedical Board of Directors.

**Contacts**

**Corporate**

Chief Financial Officer

Simon Glover

[sglover@4dmedical.com](mailto:sglover@4dmedical.com)

**Administration**

Company Secretary

Naomi Lawrie

[companysecretary@4dmedical.com](mailto:companysecretary@4dmedical.com)

**Media Enquiries**

The Capital Network (TCN)

Julia Maguire

[julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

**About 4DMedical**

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) - the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS™.

XV LVAS® and CT LVAS™ reports are prepared using 4DMedical's Software as a Service delivery model using existing clinical imaging equipment or the Company's revolutionary XV Scanner.

To learn more, please visit [www.4dmedical.com](http://www.4dmedical.com).

For personal use only